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A recent systematic review finds that pharmacists have a positive impact on various clinical 





This study aimed to evaluate the impact of pharmacists’ interventions on clinical asthma 
outcomes on adult patients and to identify the outcome indicators used.  
PubMed, Scopus, WoS and Scielo were searched. Studies addressing pharmacists’ interventions 
on adult asthma patients reporting clinical asthma outcomes were incorporated. 
Eleven clinical outcomes were identified in twenty-one studies. Ten studies measured the impact 
of the intervention on asthma control. Randomised and non-randomised controlled trials found 
positive results in percentages of controlled patients and Asthma Control Questionnaire scores. 
Discordant results were found for Asthma Control Test results. Asthma severity was assessed in 
four studies. A randomised controlled trial found a significant decrease in the percentage of 
severe patients, two non-randomised controlled trials found significant improvements in severity 
scores. Eleven studies reported pulmonary function indicators, showing inconsistent results. 
Eight studies measured asthma symptoms; three randomised controlled trials and four non-
randomised controlled trials showed significant improvements. 
Randomised and non-randomised controlled trials generated similar results for most outcomes. 
Based on the evidence generated by randomised controlled trials, pharmacists’ have a positive 
impact on the percentage of controlled patients, Asthma Control Questionnaire scores, severity 
and symptoms. Future research should report using the core outcome set of indicators 






According to World Health Organization estimates[1], 235 million people worldwide suffer from 
asthma, making it a major health problem in industrialised countries. The social impact of 
asthma is high, with negative clinical, economic and humanistic implications[2] mainly due to 
ineffective management of the disease. 
Good asthma outcomes hinge on the accessibility to effective medications and their appropriate 
use by patients. Regular reviews with a healthcare provider are an essential component for 
effective asthma management[3]. Asthma education and training can be delivered effectively by 
different health care providers such as physicians, nurses or pharmacists. Given that many of the 
issues associated with suboptimal asthma management are related to the inappropriate use of 
medications[4, 5], pharmacists are in an excellent position to play an active and positive role in 
the management of asthma. The change in pharmacists’ practice in health care to a more patient 
centred approach, through the provision of professional pharmacy services, supports and 
focuses on optimising medicines use and improving health outcomes. Several meta-analyses 
have shown a positive impact of pharmacists when delivering clinical services for patients with 
chronic conditions such as diabetes[6] or hypertension[7]. Similarly, a literature review found 
that community pharmacists can play an effective role in screening for poorly controlled asthma 
and undiagnosed COPD by delivering management interventions[8]. A narrative review revealed 
an expanding role in asthma care across different settings[9]. However, no systematic review of 
pharmacists’ impact on asthma outcomes has been found.  
Selecting appropriate outcomes when designing any research study is crucial when reporting the 
results of the research, since it allows analysing the effects of different interventions in ways that 
minimise bias[10]. However, there seems to be a high variability in the literature when reporting 
the effects of interventions on asthma patients. Difficulties caused by the heterogeneity of 
outcome measurements are common. This heterogeneity has direct implications when 
comparing and analysing the evidence available. However this problem could be addressed by 
the design of a ‘core outcome set’, which is an agreed minimum set of outcomes or outcome 
measures (The COMET Initiative: http://www.comet-initiative.org)[11]. This implies a 
standardisation of the variables that should be measured and reported in all trials in a specific 
area. Although there is a growing recognition of its relevance and some work has already been 
undertaken in childhood asthma, to our knowledge no core outcome set has been established 
for adult asthma patients in community care.  
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The objective of this systematic review was to evaluate the impact of pharmacists’ interventions 
on clinical asthma outcomes on adult patients and to identify the clinical outcome indicators 
reported in experimental studies to assess them. 
 
MATERIAL AND METHODS 
A systematic review was undertaken following the methodological and reporting standards 
recommended by PRISMA[12] and AMSTAR[13]. A literature search was conducted in August 
2015. Neither publication date nor publication type filters were used. Studies assessing 
pharmacist interventions on adult asthma patients reporting clinical asthma outcomes as a result 
of the intervention provided were included. The studies eligible were those published or at least 
with an abstract and written with the Latin alphabet. Searches were conducted in PubMed, 
Scopus, Web of Science and Scielo. The queries used are described in Table 1. Duplicates records 
were removed.  
 
 
Table 1. Search strategies used in the literature retrieval 
PubMed: 
 (“Medication Adherence”[MH] (“Patient Compliance”[MH] AND “Drug Therapy”[MH]) OR 
“Patient education as topic” OR “Program Evaluation”[MH] OR “Outcome and Process 
Assessment (Health Care)”[MH] OR “Educational Measurement” [MH] OR “Patient Care 
Management” [MH] OR “Preventive Health Services” [MH] OR “Health Behavior” [MH] OR 
“Follow-Up Studies”[MH]) 
AND 
((Pharmacists OR Pharmacists [MH] OR “Pharmaceutical Services”[MH] OR Pharmacies OR 
Pharmacies [MH])) 
AND 




KEY (Pharmacist OR Pharmacy OR “community pharmacy” OR “hospital pharmacy” OR 
“pharmaceutical care”) 
AND  
KEY (asthma OR  "antiasthmatic agent") 
AND  
KEY (“disease severity” OR “forced expiratory volume” OR “forced vital capacity” OR “outcome 
assessment” OR spirometry OR “disease control” OR “treatment outcome” OR “point of care 
testing” OR “patient compliance” OR “patient education” OR “patient care” OR “medication 
compliance” OR “patient counseling” OR counseling OR “Asthma Control Questionnaire” OR 
“Asthma Control Test” OR “asthma therapy assessment questionnaire” OR “Asthma Control 
Scoring System”) 
Web of Science: 
 (TS=(pharmacist* NEAR intervention)) AND (TS=asthma) 
Scielo: 
 ((asma) AND (farmaceutico*)) OR (asthma AND pharmacist*) 
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The literature selection process was undertaken and discussed between two experts on asthma 
services (FFL, VGC). To identify potentially relevant articles, a screening of records retrieved from 
the search was performed by reviewing titles and abstracts. This process was over-inclusive. 
Obviously irrelevant records were removed. Potentially relevant articles were retrieved and 
multiple reports of the same study were linked together. Full-text papers not discarded in the 
screening were read, and studies were excluded according to the following criteria: (1) non-
experimental studies, (2) studies with asthma patients younger than 18 years old, (3) studies not 
reporting a clinical asthma outcome (e.g. asthma control, asthma severity, asthma symptoms, 
peak expiratory flow, forced expiratory volume in the first second, or other pulmonary function 
indicator) (4) studies in which the educational intervention was not exclusively provided by a 
pharmacist. The reference lists of the retrieved papers were reviewed for potentially additional 
relevant studies.  
 
Relevant information from all included studies was gathered in a pre-designed and piloted data 
extraction form. The following information was extracted: - Source: Study ID, citation and 
contact details - Eligibility: Confirmation of inclusion criteria - Objective - Methods: Study design, 
study groups, follow-up time, sequence generation, allocation sequence concealment, blinding - 
Participants: Total number of patients, total number of practices, setting, country, 
Inclusion/exclusion criteria. - Interventions: Number of intervention groups, intervention details, 
outcomes, outcomes definition, method of assessment, characteristics of the method of 
assessment (If ad-hoc). - Results: Number of patients and practices allocated to each group, 
sample size, missing participants, subgroup analysis. - Summary of data: summary of results for 
each clinical asthma outcome assessed - Conclusions - Miscellaneous: Funding source, references 
to other relevant studies, reviewer´s comments.  
 
Following AMSTAR recommendations, data synthesis and conclusions were formulated taking 
into consideration the epidemiological design of the studies[13]. The systematic review was 
registered in the PROSPERO -International Prospective Register of Systematic Reviews- database 
(registration#CRD42014007019), where a detailed protocol of the review can be found.  
RESULTS 
Initially, 1194 different potential articles were retrieved from the databases used. After 
screening by title and abstract, 68 of them were selected for full-text review. In the second step, 
41 were excluded for the following reasons (papers could be excluded due to more than one 
criterion): six were non-experimental studies, twenty-two included a population under eighteen 
years old, in ten the intervention was not delivered exclusively by a pharmacist and nineteen did 
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not evaluate any clinical asthma outcome. Twenty-four papers corresponding to twenty-one 
studies were included (Figure 1). Fourteen studies were conducted in a community pharmacy 
setting[14-27], two in a hospital setting[28, 29], two in a community clinic setting[30, 31], one in 
an outpatient medical centre[32], one in an antenatal outpatient clinic[33] and one was 
conducted by telephone[34]. Seven studies were conducted under a randomised controlled trial 
design (RCT)[16, 17, 22, 28, 29, 33, 34], two under a cluster randomised controlled trial (C-RCT) 
design[14, 19], two under a cluster randomised trial design (C-RT)[15, 26], two under a cluster 
controlled trial design[24, 25] and eight under a quasi-experimental study with no control group 
design[18, 20, 21, 23, 27, 30-32]. The follow-up period varied across the studies, ranging 
between one month[20, 26], two months[28], three months[16, 29], five months[18], six 
months[14, 15, 17, 19, 22, 23, 27, 31, 33, 34], nine months[25], twelve months[21, 24] and 
twenty-four months[30]. The follow-up period was not specified in one of the studies 
retrieved[32]. The main characteristics of the studies are summarised in the supplementary 
material. 
Impact of pharmacist interventions on clinical asthma outcomes 
 
Current asthma control 
Ten studies measured the impact of a pharmacist intervention on current asthma control as a 
main outcome[15, 17, 19, 20, 22, 25-27, 33, 34]. It was mainly assessed using validated 
instruments, such as the Asthma Control Questionnaire (ACQ) and the Asthma Control Test 
(ACT). Four studies reported a change in the number of controlled asthma patients[15, 19, 22, 
27] and ten studies reported a change in either ACQ[15, 19, 20, 25, 26, 33] or ACT [17, 22, 27, 34] 
scores.  
Five studies that measured current asthma control as a main outcome used either a RCT or a C-
RCT design[17, 19, 22, 33, 34]. The two RCTs/C-RCTs that measured the change in the number of 
controlled asthma patients, reported an improvement in the percentage of patients considered 
to have good asthma control[19, 22]. Results showed that the difference in the percentage of 
controlled patients between study groups after the provision of the intervention was 12.1% 
(p=0.028) and 7.7% (no p-value provided) respectively. One of the studies found that patients in 
the intervention group were almost three times more likely to have their asthma controlled than 
patients in the control group (OR 3.06,95% CI:1.63-5.73;p<0.001). The two RCT/C-RCT assessing 
the change in ACQ scores also found a positive impact, since both statistically and clinically 
significant reductions in patient’s ACQ scores were observed[19, 33]. One study found a 
difference in ACQ scores between study groups after the provision of the intervention of 0.41 
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points (p<0.001)[19], whereas in another the difference was equal to 0.60 (p<0.001)[33]. Only 
one of the three RCTs evaluating the change in ACT scores found significant improvements in the 
intergroup comparisons[17]. This study found a difference in asthma control scores between 
study groups after the intervention equal to 2.6 (p<0.01). 
The other five studies that measured current asthma control used different research designs[15, 
20, 25-27]. Two of them assessed the change in the number of controlled patients, signalling 
positive findings[15, 27].  One study assessed the impact of two different interventions, 
reporting a significant improvement in the percentage of patients considered to have good 
asthma control after both interventions were delivered (increase of 32% and 38% respectively, 
no p-value provided for the intragroup comparisons)[15]. Four studies reported the change in 
ACQ scores[15, 20, 25, 26].  These four found significant reductions in ACQ scores, ranging from 
0.56 and 0.57 (no p-value provided), 0.4 (p<0.001), 0.23 (p=0.02), and 0.4 (p=0.003) respectively. 
One study reported statistical and clinical significant reductions, since 48% of patients 
demonstrated a reduction greater or equal to 0.5 in their ACQ scores[15].  
Asthma Severity 
The impact of pharmacy interventions on asthma severity was assessed in four studies[14, 21, 
23, 24]. The methods of assessment varied; two studies used the criteria established by the 
German Asthma Guidelines[21, 24], one used a tool based on the National Asthma Council 
Australia severity score[14], whereas another based the assessment on the criteria established 
by the Australian Asthma Management Handbook[23]. In terms of the impact of the pharmacist 
intervention, one study reported the change in the number of patients suffering from severe 
asthma[14], and three studies used the change in mean asthma severity scores as their outcome 
indicator.  
 
The only RCT assessing the impact of a pharmacist intervention on asthma severity reported a 
significant decrease in the percentage of patients having severe asthma[14]. This study reported 
a significant decrease in the proportion of severe patients from 87.9% to 52.7% (p<0.001), while 
the control group remained unchanged. The authors also found that patients in the intervention 
group were more likely to change from the severe to the not severe category than patients in the 
control group (OR 2.68, p<0.001).  
Three further studies assessing asthma severity as a main outcome indicator used a non-
randomised design. Two studies reported significant decreases in mean asthma severity scores 




Eleven studies reported some measurement of pulmonary function as an outcome indicator of 
the intervention designed[14, 18, 21-24, 27-30, 32]. Seven reported changes in Peak Expiratory 
Flow (PEF) values[18, 21-24, 29, 30], six in Forced Expiratory Volume in the First second (FEV1) 
values[14, 21, 24, 28, 32, 35], one in Vital Capacity (VC)[21], one in FEV1 % VC (FEV1 expressed as 
a percentage of the VC, Tiffeneau index)[21], one in Forced Vital Capacity (FVC)[32] and one in 
FEV1/FVC ratio[14]. Methods of evaluation and reporting of outcome indicators diverged. PEF 
values were either measured at the pharmacy[18, 21, 24, 29, 30] or self-measured by the 
patient[22-24]. Results were expressed as PEF rate[18, 21, 24, 29], percentage of maximum 
predicted PEF[22], peak flow index[23] and number of patients below 70% and 85% of optimal 
PEFR[30]. In terms of FEV1 values, they were measured by a pharmacist[14] or by a 
physician[21]. This information remained unknown in four studies[24, 27, 28, 32]. Results were 
reported as percentage predicted[14, 27], as an absolute number[21, 28], as a mean percentage 
change[32], as a percentage change from baseline[24] and as a percentage of the VC[21]. The 
study assessing VC reported it in absolute values[21] whereas the one measuring FVC, as mean 
percentage change[32]. The only study measuring FEV1/FVC reported it as a percentage of 
predicted value[14].  
Four out of the ten studies evaluating any pulmonary function outcome indicator used a RCT 
design[14, 22, 28, 29]. No studies reported improvements in percentage of maximum PEF[22] or 
PEF rate[29]. However, one RCT did report significant improvements in FEV1 values after the 
intervention[28] (difference of 0.20 L between study groups, no p-value provided). One C-RCT 
evaluated the change in percentage of predicted FEV1/FVC, with no change after the follow-up 
[14].  
Results from non-RCT showed two studies reporting improvements in PEF rates[18, 21]. In the 
first study, PEF rates ranging from 0.13 to 0.12L/min (no p-value provided) were found. In the 
second one, an improvement of 0.35L/min (p<0.001) was reported. Only one study was 
identified as using peak flow index as an outcome indicator [23], with results showing significant 
improvements after the intervention [from 82.7%±8.2% to 87.4%±8.9% (p<0.001)]. In terms of 
other outcomes, one study showed significant improvements in the percentage of predicted 
FEV1 [from 46.6%±0.09 to 70.4%±0.10 (p<0.05)][27]. One study reported significant 
improvements of mean percentage changes in FEV1 values (18.5L ± 1.5 in the intervention group 
vs 5.2 ± 1.0 in the comparison group, no p-value provided) but no differences in FVC[32]. Two 
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studies did not find any effect on other pulmonary function indicators such as VC, FVC or 
FEV%VC[21, 32] 
Asthma symptoms 
Eight studies reported the impact of the pharmacist intervention on asthma symptoms. Three of 
them assessed the occurrence of general asthma symptoms[16, 21, 30], evaluated with the 
validated North England Asthma Symptoms Scale, with a self-reported measure and with an ad-
hoc questionnaire.  This outcome was reported as a mean symptoms score[16], as a self-scored 
punctuation[21] and as a mean number of symptoms suffered in the previous week[30]. Four 
studies assessed the occurrence of nocturnal asthma symptoms as outcome indicators, including 
mean nocturnal episodes of asthma[31], mean frequency of nocturnal asthma symptoms[29], 
number of nocturnal awakenings due to asthma[22], and sleep disturbances [18]. Two studies 
used a self-reported card/diary to assess asthma nocturnal episodes[22, 29], whereas the 
method of assessment was not specified in two studies[18, 31]. Two studies assessed dyspnoea 
severity[21, 24], rated by the patient’s physician through the Medical Research Council dyspnoea 
scale.   
Amongst the three RCTs[16, 22, 29], one showed a significant improvement in the mean asthma 
symptoms score[16], with a mean difference in asthma symptoms scores between study groups 
after the intervention equal to 7 (p<0.001). Two studies reported positive outcomes in terms of 
nocturnal asthma symptoms[22, 29]; one reported a difference in mean change of nocturnal 
awakenings between study groups equal to 3.5 (p=0.004) and the second found that patients in 
the intervention group had a greater significant decrease in the mean frequency of nocturnal 
symptoms than patients in the control group after 20 and 22 weeks of follow-up (no mean values 
provided, p<0.05). 
Of the five non-randomised studies assessing the impact on asthma symptoms, one study found 
a reduction in the number of patients with moderate or severe symptoms[30] (no p-value 
provided). Two studies reported positive findings in terms of nocturnal asthma symptoms[18, 
31], and one in terms of dyspnoea severity scores[21].  
Table 2 shows a summary of the pharmacists’ impact on the different asthma outcomes 




Table 2. Summary of findings of the impact of pharmacists’ interventions on asthma outcomes 







Current asthma control 
% Controlled patients (+)[19, 22]** (+)[15, 
27]** 
ACQ Scores (+)[19, 33] (+)[15, 20, 
25, 26] 




% Severe patients (+)[14] NEA 





PEF rate (+-)[29] (+)[18, 21]  
(+-)[24] 
Percentage of maximum predicted PEF (+-)[22] NEA 
Peak Flow Index NEA (+) [23] 
PEF values below 85% of optimal PEF NEA (+) [30] ** 
PEF values under 70% of optimal PEF NEA (+) [30] ** 
FEV1 
Percentage of predicted personal best (+-)[14] (+)[27] 
FEV1 (absolute number) (+)[28]** (+)[21] ** 
Mean percentage change NEA (+-)[32]  
Percentage change of FEV1 from 
baseline 
NEA (+-)[24]  
VC Absolute value NEA (+-)[21] 
FVC Mean percentage change NEA (+-)[32] ** 
FEV1/FVC Percentage of FEV1/FVC predicted value 
(+-)[14] NEA 






Mean asthma symptoms score (+)[16] NEA 
Self rated score  NEA (+)[21] 
Mean number of symptoms in 
previous week 
NEA (+)[30] ** 
Nocturnal 
symptoms 
Mean nocturnal episodes of asthma NEA (+)[31] 
Mean frequency of nocturnal asthma 
symptoms 
(+) [29] NEA 
Number of nocturnal awakenings due 
to asthma 
(+)[22] NEA 
Number of patients with sleep 
disturbances 
NEA (+)[18]** 
Dyspnoea Dyspnoea severity score NEA (+)[21] 
(+-)[24] 
RCT: Randomised controlled trial, C-RCT: Cluster randomised controlled trial 
(+): Positive findings, (+-): Neutral findings 
NEA: No evidence available 
** no p-value provided 
ACQ Asthma Control Questionnaire; ACT: Asthma Control Test; PEF: Peak Expiratory Flow; FEV1:  Forced Expiratory Volume in the first second; 





The use of statistical techniques was attempted to integrate and summarize the results reported 
for clinical asthma outcomes. However, a meta-analysis could not be performed due to the lack 
of some statistical parameters needed as well as the variability in the different outcomes 
assessed and epidemiological designs used. Although nine studies satisfied all the requirements 
for meta-analysis, it was not undertaken as the high heterogeneity would have generated 
evidence of poor quality (Table 3). 
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Lack of standard deviation of mean change for control group 
Armour et al (2013)[15] Lack of control group 
Giraud et al[20] Lack of control group 
Smith et al[25] Lack of standard deviation of mean change for both study groups 
Lim et al[33] Appropriate for meta-analysis 
Toumas-Sehata et al[26] Lack of control group 
ACT scores Mehuys et al[22] Appropriate for meta-analysis 
Young et al[34] Lack of standard deviation of mean difference  
Bereznicki et al[17] Lack of baseline results for control group. Lack of mean change 
and standard deviation of both study groups 
Asthma 
severity 
Mangiapane et al[21] Lack of control group 
Saini et al[23] Lack of standard deviation of mean for both groups 
Schulz et al[24] Lack of standard deviation of mean for both groups  
PEF Mangiapane et al[21] Lack of control group 
Saini et al[23] PEF values only in intervention group  
Mehuys et al[22] Appropriate for meta-analysis 
Abdelhamid et al[29] Lack of outcome values before and after in both study groups  
Petkova et al[18] Lack of control group 
Schulz et al[24] Lack of standard deviation of mean change for both study groups  
Narhi et al[30] Lack of control group 
FEV1 Mangiapane et al[21] Lack of control group 
Kumar et al[28] Lack of standard deviation of mean change for both study groups 
Schulz et al[24] Appropriate for meta-analysis 
Armour et al (2007)[14] Appropriate for meta-analysis 
de Tullio et al[32] Lack of standard deviation of mean change and p value for both 
study groups 
Zanghelini et al[27] Lack of control group 
VC Mangiapane et al[21] Appropriate for meta-analysis 
FVC de Tullio et al 1987[32]  Results not reported 
FEV1/FVC Armour et al[14] Appropriate for meta-analysis 
FEV1%VC Mangiapane et al[21] Appropriate for meta-analysis 
Asthma 
symptoms 
Barbanel et al[16] Appropriate for meta-analysis 
Mehuys et al[22] Appropriate for meta-analysis 
Petkova et al[18] Lack of control group 
Narhi et al[30] Lack of control group 
Odegard et al[31] Lack of control group 
Abdelhamid et al[29] Appropriate for meta-analysis 
Mangiapane et al[21]  Lack of control group 
Schulz et al[24]  Lack of standard deviation of mean change for both study groups  
Dichotomous outcomes  
Asthma 
control 
Mehuys et al[22] Appropriate for meta-analysis 
Armour et al[15] Appropriate for meta-analysis 
Garcia-Cardenas et 
al[19] 
Appropriate for meta-analysis 
Zanghelini et al[27] Lack of control group 
Asthma 
severity 
Armour et al (2007)[14] Appropriate for meta-analysis 




This systematic review identified twenty-one studies assessing the impact of pharmacists’ 
interventions on asthma outcomes in adult patients. A large variety of outcomes were used to 
demonstrate such impact, including different measures of asthma control, asthma severity, 
pulmonary function and asthma symptoms.  
RCTs/C-RCTs generated similar results to those generated by non-RCT for most of the outcomes 
assessed. Nine out of ten studies assessing asthma control revealed a positive impact after the 
provision of the pharmacist´s intervention. For example, all studies reporting changes in the 
percentage of controlled asthma patients, found a positive association between pharmacist’s 
intervention and current asthma control [15, 19, 22]. Similar results were observed in terms of 
ACQ scores, with all six studies reporting significant improvements for this outcome[15, 19, 20, 
25, 26, 33]. Two of the four studies measuring ACT scores found a similar trend[17, 27]. Studies 
assessing any measure of asthma severity also supported the potential role of pharmacists on 
asthma management. Pharmacists contributed to a significant reduction in the percentage of 
severe patients and asthma severity scores in three of the four studies assessing this 
outcome[14, 21, 23, 24]. Both RCT and non-RCT assessing pulmonary function measures, failed 
to demonstrate a significant impact on VC, FVC, FEV1/FVC and FEV1%VC. However, 
improvements were identified in terms of PEF and FEV1[18, 21, 23, 27, 28, 30, 32]. Regardless of 
the study design, pharmacists were found to have a positive impact on different measures of 
asthma symptoms. For example, all seven studies assessing general or nocturnal symptoms as 
their main outcome reported improvements after the provision of the intervention[16, 18, 21, 
22, 29-31]. It is evident that both RCTs/C-RCTs and non-RCT yielded similar trends, highlighting 
the potential role of pharmacists in asthma management. However, appropriately designed, 
conducted and reported RCTs/C-RTCs represent the gold standard in assessing healthcare 
interventions[36]. Future research aimed at assessing pharmacists’ interventions on asthma 
outcomes should utilize these research designs. Nevertheless, further experimental designs can 
be considered if a conventional RCT design is not feasible[37]. The use of other research designs 
would also be of great interest, allowing the assessment of the interventions´ elements. It is 
worthwhile mentioning that amongst the included studies, many different interventions with 
several interacting components were tested. This heterogeneity may have impacted the 
outcomes achieved, and may account for the differences between significant and non-significant 
findings. As the effect of the different intervention elements was not independently assessed in 
any of the studies, those with the biggest impact on clinical asthma outcomes remain unknown.  
 14 
Within the twenty-one included studies, eleven different clinical outcomes and twenty-six 
different reporting systems were identified, hindering the synthesis of the evidence available. As 
in other conditions [38, 39], it is necessary to agree on a core outcome set to be measured and 
reported in all the studies assessing the impact of health interventions on adult asthma patients. 
The selection of appropriate outcomes to measure allows the analysis of the effects of different 
interventions and minimises bias[10]. This provides not only a reliable comparison of results 
across different studies, but also an evaluation of the consistency of the research findings when 
translated into clinical practice. The core outcome set for asthma interventions must be 
established in accordance with updated evidence based reports, such as the Global Initiative for 
Asthma (GINA). In its latter update, GINA recommends the assessment of asthma control based 
on two different domains: symptom control (previously known as current clinical control) and 
future risk of adverse outcomes (including risk factors for exacerbations, fixed airflow limitation 
and medication side-effects)[3]. This implies that both domains should always be assessed and 
reported separately. The application of this approach to assess the impact of pharmacists’ 
interventions seems to be feasible. We suggest that studies assessing pharmacist interventions 
in clinical trials always report at least symptom control and specific indicators of risk of adverse 
outcomes as a core outcome set, described as follows. The assessment of symptoms control 
should be done using validated tools, such as the ACQ and the ACT. These instruments have 
already been used in several intervention studies with positive results[15, 17, 19, 20, 25-27, 33, 
34]. In terms of a future risk of adverse outcomes assessment; at least short-acting beta2-agonist 
use, adherence to inhaled corticosteroids, inhaler technique, exposure to triggers, and 
potentially FEV1, should be measured and reported. None of the studies included in this review 
reported all the aforementioned outcomes. This might be explained by the fact that first asthma 
severity, and then current clinical control, have traditionally been the ultimate outcomes of 
asthma management.  
A meta-analysis of the studies was attempted to estimate the pooled effects of pharmacists’ 
interventions on asthma outcomes. However, some factors impeded its performance, such as 
the variability on the different outcomes assessed and the reporting systems used, together with 
lack of statistical parameters. Different guidelines for reporting experimental studies such as 
CONSORT[35], have been developed to assist authors in writing manuscripts, and journal editors 
and peer reviewers in evaluating them for publication. This has undoubtedly helped to increase 
the quality of data available in the scientific community. However, whilst key statistical 
parameters are missing or high variability remains common, identifying a real effect of an 
intervention will not be possible.  
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A potential limitation of this systematic review is that some studies undertaken in the early 
2000´s, assessing the role of pharmacists on asthma management were retrieved in our search 
strategy but not included in the analysis[40-42]. These papers included children as well as adults, 
and we reviewed studies which dealt with adults only. Although our query intended to retrieve 
all published studies evaluating the effect of pharmacists’ interventions in clinical asthma 
outcomes, publication bias may have occurred because no grey literature was included. 
However, since no papers were retrieved from additional references, it seems that high-
sensitivity queries were used. This may also be explained due to the number of databases used, 
covering most of the published data in our research area. Due to the low number of RCTs/C-RCTs 
identified, studies with different experimental research designs were included. This impeded 
performing a risk of bias assessment. However, following AMSTAR recommendations, this was 
taken into account for the data synthesis and formulation of the conclusions of this review[13]. 
Moreover, the potential differing quality of the studies included did no affect the main objective 
of our review.   
In conclusion, the evidence of pharmacists’ interventions on clinical asthma outcomes in adult 
patients has been evaluated using heterogeneous outcomes, including different measures of 
asthma control, asthma severity, pulmonary function, and asthma symptoms. Based on the 
evidence generated by RCTs/C-RCT, pharmacists’ interventions have a positive impact on the 
percentage of asthma-controlled patients, ACQ scores, asthma severity and asthma symptoms. 
Inconsistent impact has been found in terms of ACT scores and pulmonary function indicators.  
Future research evaluating the impact of pharmacists’ interventions on clinical asthma outcomes 
should report using a core outcome set of indicators established for this condition, based on 
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